[U.S. approves generic version of powerful AIDS drug] November 4th, according to "Science" report, on November 2, the U.S. Food and Drug Administration (FDA) officially approved the AIDS prevention drug - a generic version of Napavir for injection. One dose of the generic drug provides six months of protection against HIV infection, and its Indian manufacturer, Dr. Reddy's Laboratories, has pledged to sell the drug for just $40 per person per year. The decision by U.S. regulators is expected to speed up the delivery of powerful HIV prevention drugs in low-income countries with high infection rates. Lenapavir was developed by the American biopharmaceutical company Gilead. In June 2025, the FDA approved it as a "pre-exposure prophylaxis" drug. Two doses provide a year of protection and cost about $28,000. Gilead has previously agreed to provide lenapavir to the Global Fund to Fight AIDS, Tuberculosis and Malaria (hereinafter referred to as the Global Fund) at a not-for-profit price. According to sources, the price is $120 per person per year. The Global Fund currently funds disease prevention and treatment efforts in more than 100 countries.